{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T04:09:42Z","timestamp":1784779782008,"version":"3.55.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"South African Research Chairs Initiative"},{"DOI":"10.13039\/100014305","name":"HIV Research Trust","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100014305","id-type":"DOI","asserted-by":"crossref"}]},{"name":"National Health Laboratory Service Research Trust"},{"DOI":"10.13039\/501100001323","name":"Poliomyelitis Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001323","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s12985-016-0628-x","type":"journal-article","created":{"date-parts":[[2016,10,12]],"date-time":"2016-10-12T12:51:20Z","timestamp":1476276680000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Pre-treatment minority HIV-1 drug resistance mutations and long term virological outcomes: is prediction possible?"],"prefix":"10.1186","volume":"13","author":[{"given":"M. L.","family":"Mzingwane","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. T.","family":"Tiemessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. L.","family":"Richter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. H.","family":"Mayaphi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Hunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. M.","family":"Bowyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,10,12]]},"reference":[{"issue":"1","key":"628_CR1","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jinf.2013.09.005","volume":"68","author":"N Bulteel","year":"2014","unstructured":"Bulteel N, Bansi-Matharu L, Churchill D, et al. The emergence of drug resistant HIV variants at virological failure of HAART combinations containing efavirenz, tenofovir and lamivudine or emtricitabine within the UK Collaborative HIV Cohort. J Infect. 2014;68(1):77\u201384.","journal-title":"J Infect"},{"issue":"11","key":"628_CR2","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1093\/cid\/civ656","volume":"61","author":"TS Boender","year":"2015","unstructured":"Boender TS, Hoenderboom BM, Sigaloff KC, et al. Pretreatment HIV drug resistance increases regimen switches in Sub-Saharan Africa. Clin Infect Dis. 2015;61(11):1749\u201358.","journal-title":"Clin Infect Dis"},{"key":"628_CR3","doi-asserted-by":"crossref","unstructured":"Kantor R, Smeaton L, Vardhanabhuti S, et al. Pre-treatment HIV drug resistance and HIV-1 subtype C are independently associated with virologic failure: results from the multi-national PEARLS (ACTG A5175) clinical trial. Clin Infect Dis. 2015;60(10):1541\u20139.","DOI":"10.1093\/cid\/civ102"},{"issue":"1","key":"628_CR4","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1097\/QAI.0000000000000108","volume":"66","author":"P Phanuphak","year":"2014","unstructured":"Phanuphak P, Sirivichayakul S, Jiamsakul A, et al. Transmitted drug resistance and antiretroviral treatment outcomes in non-subtype B HIV-1-infected patients in South East Asia. J Acquir Immune Defic Syndr (1999). 2014;66(1):74\u20139.","journal-title":"J Acquir Immune Defic Syndr (1999)"},{"key":"628_CR5","unstructured":"European AIDS Clinical Society. Guidelines version 8.0, October 2015. http:\/\/www.eacsociety.org\/files\/guidelines_8_0-english_web.pdf . Accessed 26 Oct 2015."},{"key":"628_CR6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1468-1293.2011.00971.x","volume":"1","author":"D Asboe","year":"2012","unstructured":"Asboe D, Aitken C, Boffito M, et al. British HIV Association guidelines for the routine investigation and monitoring of adult HIV-1-infected individuals 2011. HIV Med. 2012;1:1\u201344.","journal-title":"HIV Med"},{"key":"628_CR7","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1086\/655397","volume":"202","author":"S Gianella","year":"2010","unstructured":"Gianella S, Richman DD. Minority variants of drug-resistant HIV. J Infect Dis. 2010;202:657\u201366.","journal-title":"J Infect Dis"},{"key":"628_CR8","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1146\/annurev-genom-091212-153406","volume":"15","author":"S Chabria","year":"2014","unstructured":"Chabria S, Gupta S, Kozal MJ. Deep sequencing of HIV: clinical and research applications. Annu Rev Genomics Hum Genet. 2014;15:295\u2013325.","journal-title":"Annu Rev Genomics Hum Genet"},{"issue":"4","key":"628_CR9","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1086\/650001","volume":"50","author":"MR Jakobsen","year":"2010","unstructured":"Jakobsen MR, Tolstrup M, S\u00f8gaard OS, et al. Transmission of HIV-1 drug-resistant variants: prevalence and effect on treatment outcome. Clin Infect Dis. 2010;50(4):566\u201373.","journal-title":"Clin Infect Dis"},{"issue":"12","key":"628_CR10","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1097\/QAD.0b013e3283034953","volume":"22","author":"O Peuchant","year":"2008","unstructured":"Peuchant O, Thi\u00e9baut R, Capdepont S, et al. Transmission of HIV-1 minority-resistant variants and response to first-line antiretroviral therapy. AIDS. 2008;22(12):1417\u201323.","journal-title":"AIDS"},{"issue":"1","key":"628_CR11","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/QCO.0000000000000136","volume":"28","author":"AM Geretti","year":"2015","unstructured":"Geretti AM, Paredes R, Kozal MJ. Transmission of HIV drug resistance: lessons from sensitive screening assays. Curr Opin Infect Dis. 2015;28(1):23\u201330.","journal-title":"Curr Opin Infect Dis"},{"issue":"13","key":"628_CR12","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1001\/jama.2011.375","volume":"305","author":"JZ Li","year":"2011","unstructured":"Li JZ, Paredes R, Ribaudo HJ, et al. Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis. JAMA. 2011;305(13):1327\u201335.","journal-title":"JAMA"},{"key":"628_CR13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0010952","volume":"5","author":"M Lataillade","year":"2010","unstructured":"Lataillade M, Chiarella J, Yang R, et al. Prevalence and clinical significance of HIV drug resistance mutations by ultra-deep sequencing in antiretroviral-naive subjects in the CASTLE study. PLoS One. 2010;5, e10952.","journal-title":"PLoS One"},{"key":"628_CR14","first-page":"662","volume":"201","author":"R Paredes","year":"2010","unstructured":"Paredes R, Lalama CM, Ribaudo HJ, et al. Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure. J Infect Dis. 2010;201:662\u201371.","journal-title":"J Infect Dis"},{"key":"628_CR15","unstructured":"National consolidated guidelines for the prevention of mother to child transmission of HIV (PMTCT) and management of HIV in children, adolescents and adults. National Department of Health, South Africa. 2015. http:\/\/www.health.gov.za\/index.php\/2014-03-17-09-09-38\/policies-andguidelines\/category\/230-2015p# #. Accessed 26 Oct 2015."},{"issue":"6","key":"628_CR16","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1089\/aid.2011.0284","volume":"28","author":"J Manasa","year":"2012","unstructured":"Manasa J, Katzenstein D, Cassol S, Newell ML, de Oliveira T. Southern Africa Treatment And Resistance Network (SATuRN). Primary drug resistance in South Africa: data from 10\u00a0years of surveys. AIDS Res Hum Retroviruses. 2012;28(6):558\u201365.","journal-title":"AIDS Res Hum Retroviruses"},{"key":"628_CR17","volume":"85","author":"J Manasa","year":"2014","unstructured":"Manasa J, Danaviah S, Pillay S, et al. An affordable HIV-1 drug resistance monitoring method for resource limited settings. J Vis Exp. 2014;85, e51242.","journal-title":"J Vis Exp"},{"key":"628_CR18","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S1473-3099(09)70328-7","volume":"10","author":"RE Barth","year":"2010","unstructured":"Barth RE, van der Loeff MFS, Schuurman R, Hoepelman AL, Wensing AM. Virological follow-up of adult patients in antiretroviral treatment programmes in sub-saharan Africa: a systematic review. Lancet Infect Dis. 2010;10:155\u201366.","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"628_CR19","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1093\/jac\/dku377","volume":"70","author":"M Pingen","year":"2015","unstructured":"Pingen M, Nijhuis M, Mudrikova T, van Laarhoven A, Langebeek N, Richter C, Boucher CA. Infection with the frequently transmitted HIV-1 M41L variant has no influence on selection of tenofovir resistance. J Antimicrob Chemother. 2015;70(2):573\u201380.","journal-title":"J Antimicrob Chemother"},{"issue":"7","key":"628_CR20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0050158","volume":"5","author":"JA Johnson","year":"2008","unstructured":"Johnson JA, Li JF, Wei X, et al. Minority HIV-1 drug resistance mutations are present in antiretroviral treatment\u2013na\u00efve populations and associate with reduced treatment efficacy. PLoS Med. 2008;5(7), e158.","journal-title":"PLoS Med"},{"key":"628_CR21","doi-asserted-by":"crossref","unstructured":"Antiretroviral Therapy Cohort Collaboration (ART-CC), Vandenhende MA, Ingle S, et al. Impact of low-levelviremia on clinical and virological outcomes in treated HIV-1-infected patients. AIDS. 2015;29(3):373\u201383.","DOI":"10.1097\/01.aids.0000471462.99382.50"},{"issue":"10","key":"628_CR22","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1089\/aid.2015.0102","volume":"31","author":"A Calcagno","year":"2015","unstructured":"Calcagno A, Motta I, Ghisetti V, et al. HIV-1 very low level viremia is associated with virological failure in highly active antiretroviral treatment-treated patients. AIDS Res Hum Retroviruses. 2015;31(10):999\u20131008.","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"1","key":"628_CR23","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1093\/infdis\/jir208","volume":"204","author":"TW Chun","year":"2011","unstructured":"Chun TW, Murray D, Justement JS, Hallahan CW, Moir S, Kovacs C, Fauci AS. Relationship between residual plasma viremia and the size of HIV proviral DNA reservoirs in infected individuals receiving effective antiretroviral therapy. J Infect Dis. 2011;204(1):135\u20138.","journal-title":"J Infect Dis"},{"key":"628_CR24","doi-asserted-by":"crossref","unstructured":"Wirden M, Todesco E, Valantin MA, et al. Low-level HIV-1 viraemia in patients on HAART: risk factors and management in clinical practice. J Antimicrob Chemother. 2015;70(8):2347\u201353.","DOI":"10.1093\/jac\/dkv099"},{"issue":"12","key":"628_CR25","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1093\/cid\/cir729","volume":"53","author":"HE Rawizza","year":"2011","unstructured":"Rawizza HE, Chaplin B, Meloni ST, et al. Immunologic criteria are poor predictors of virologic outcome: Implications of HIV treatment monitoring in resource-limited settings. Clin Infect Dis. 2011;53(12):1283\u201390.","journal-title":"Clin Infect Dis"},{"key":"628_CR26","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/1471-2334-13-113","volume":"13","author":"CJ Anude","year":"2013","unstructured":"Anude CJ, Eze E, Onyegbutulem HC, et al. Immuno-virologic outcomes and immuno-virologic discordance among adults alive and on anti-retroviral therapy at 12\u00a0months in Nigeria. BMC Infect Dis. 2013;13:113.","journal-title":"BMC Infect Dis"},{"issue":"5","key":"628_CR27","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1097\/QAI.0b013e3181d91788","volume":"54","author":"MI Datay","year":"2010","unstructured":"Datay MI, Boulle A, Mant D, Yudkin P. Associations with virologic treatment failure in adults on antiretroviral therapy in South Africa. J Acquir Immune Defic Syndr. 2010;54(5):489\u201395.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"3","key":"628_CR28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0017518","volume":"6","author":"Z El-Khatib","year":"2011","unstructured":"El-Khatib Z, Katzenstein D, Marrone G, et al. Adherence to drug re-fill is a useful early warning indicator of virologic and immunologic failure among HIV patients on first-line ART in South Africa. PLoS One. 2011;6(3), e17518.","journal-title":"PLoS One"},{"key":"628_CR29","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1097\/QAI.0b013e3182084b5a","volume":"56","author":"E Messou","year":"2011","unstructured":"Messou E, Chaix ML, Gabillard D, et al. Association between medication possession ratio, virologic failure and drug resistance in HIV-1-infected adults on antiretroviral therapy in Cote d\u2019Ivoire. J Acquir Immune Defic Syndr. 2011;56:356\u201364.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"628_CR30","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.inhe.2010.11.003","volume":"3","author":"ML Ekstrand","year":"2011","unstructured":"Ekstrand ML, Shet A, Chandy S, et al. Suboptimal adherence associated with virological failure and resistance mutations to first-line highly active antiretroviral therapy (HAART) in Bangalore, India. Int Health. 2011;3:27\u201334.","journal-title":"Int Health"},{"issue":"3","key":"628_CR31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0004724","volume":"4","author":"DE Bennett","year":"2009","unstructured":"Bennett DE, Camacho RJ, Otelea D, et al. Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One. 2009;4(3), e4724.","journal-title":"PLoS One"}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-016-0628-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T07:55:36Z","timestamp":1749628536000},"score":1,"resource":{"primary":{"URL":"http:\/\/virologyj.biomedcentral.com\/articles\/10.1186\/s12985-016-0628-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,12]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["628"],"URL":"https:\/\/doi.org\/10.1186\/s12985-016-0628-x","relation":{},"ISSN":["1743-422X"],"issn-type":[{"value":"1743-422X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,12]]},"article-number":"170"}}